Ana Rosa Saez Ibanez, Ph.D., joined the Cancer Research Institute in 2022 as a Research Analyst at the CRI Clinical Accelerator and Venture Fund. In this role, she provides intelligence on immuno-oncology drug development trends and the competitive landscape, informing CRI’s clinical trials strategy, business development activities and start-ups investment decisions.
Prior to joining CRI, Ana Rosa earned her Doctorate in Cancer Cell Biology at Uppsala University (Sweden) where she explored novel roles of receptor tyrosine kinases in promoting cancer cell migration. Following obtention of her PhD degree, Ana Rosa joined Albert Einstein College of Medicine and Icahn School of Medicine at Mount Sinai (New York) as a postdoctoral fellow, where she investigated the role of chaperone-mediated autophagy in cell fate determination and development of metastatic breast cancer. She received her B.Sc. and M.Sc. in Biology and Biomedicine from the University of Valencia (Spain).
Over the years, Ana Rosa has cultivated an interest in the different steps of the drug development process. In 2020, she was selected for the FDA-AACR oncology educational fellowship, a competitive regulatory affairs program led by the FDA OCE. In addition, she has received training in biomedical entrepreneurship and has consulted for different investment banks as a biotech equity researcher. Finally, Ana Rosa holds a chair position in the fundraising committee of Women in Autophagy, a NY non-profit built to empower women and underrepresented minorities in the field of autophagy research.